Harnessing untapped
states of matter to shape
a healthier world.

Origin’s plasma-energy based solutions are intended to penetrate all areas of life science, enhancing and saving lives through applications in medicine and agribusiness. Origin’s proprietary products are designed to provide safe and effective alternatives to current solutions, improving outcomes and lowering costs.

About Origin Origin is a privately held, clinical-stage biotechnology company founded in June 2010 to develop and commercialize our novel, patented medical technology — delivering plasma-stream therapeutic molecules generated right at the point of care. Our technology is based on Nobel prize-winning research and is designed to surpass current standards of care in efficacy, side effects, and/or cost-effectiveness.

History Origin (formerly Advanced Plasma Therapies) was founded in 2010 to become an active participant in the plasma-medicine arena. Plasma medicine is an innovative and emerging field combining plasma physics, life sciences and clinical medicine to use physical plasma for therapeutic applications. It is the subject of advanced study at major academic institutions in the United States, Russia, Germany, Japan, the United Kingdom, France and Italy.

We focused on plasma's ability to deliver specific therapeutic molecules topically. Our investigations led us to a technology that delivered therapeutic doses of nitric oxide with clinical success in wound-healing in Russia and Eastern Europe, winning the Russian Federation Prize for Science.1

We secured an option to acquire the US patent for the technology in 2011, and in 2014 raised funds from institutions, including Woodford Investment Management (one of the leading healthcare investors in the United Kingdom), that enabled us to exercise this option, acquire the technology for ourselves and embark on our regulatory strategy. We selected skin and soft-tissue infections and wound-healing as our initial target area, with a first indication in diabetic foot ulcers.

We then agreed on a medical device regulatory pathway with the FDA, enhanced the technology and commenced formal clinical trials that, if successful, will lead to the submission of a premarket approval application. These trials are currently in process.

Along the way, we strengthened our Board of Directors and our management team and widened the scope of our commercial activities. We are proud that all our founding managers remain actively involved in the business and are fully dedicated to its success.

Reference: 1. Shekhter, AB, et al. Beneficial effect of gaseous nitric oxide on the healing of skin wounds. Nitric Oxide: Biology and Chemistry. 2005;12(210-219).

The story behind our name It's quite simple—our company is dedicated to harnessing plasma-energy to transcend existing boundaries of physics and medicine. Plasma is the state of matter that is core to the origin of the universe—and, therefore, of life itself. ORIGIN is a natural name for us.

Our board of directors and management team Origin is managed by a team with decades of experience in life sciences and in building value for shareholders. They have had demonstrable success:

  • Developing and marketing pharmaceuticals and medical devices, including wound-care products
  • Administering hospitals and major healthcare delivery systems
  • Growing and operating both private and publicly traded businesses

Michael Preston Chairman and Chief Executive Officer

David R. Dantzker, MD Vice Chairman and Chief Medical Officer

Howard A. Nelson President, Agribusiness, and Chief Strategy Officer

Johnny Fernandes Chief Financial Officer

Vic Micati Non-Executive Director

Tony Brampton Non-Executive Director

A founder of Origin, Mike Preston has nearly four decades of executive and business-building experience in a wide range of industries, including finance, telecommunications, biotechnology, and media. He has founded or cofounded a number of successful companies, several of which he has led to IPOs on both sides of the Atlantic.

Mike has also used the knowledge and skills he learned as a business builder to provide strategic advice and raise capital for numerous small- and mid-cap companies. He is regulated as a corporate finance principal by the Financial Conduct Authority in the UK. He obtained an MA in Classics from Oxford University and is a Price Waterhouse-trained Chartered Accountant.

Mike is focused on leading the business development of Origin and interfacing with current and prospective shareholders.

Mike enjoys a wide range of interests, including classical music (listening and playing), literature, food and wine, Arsenal Football Club and other sports, and travelling. He enjoys teaching Latin and Greek. He has four children and three grandchildren. Top

Dr. David Dantzker is an internationally recognized expert in pulmonary medicine and critical care and, as General Partner of the venture capital firm Wheatley Partners LP, has managed their medical technology portfolio for 14 years, where he participated in the financing of Dermagraft® and its sale to Shire Plc for $750 million. Prior to that, he was President of North Shore-Long Island Jewish Health System, the third largest integrated health delivery system in the United States.

David has extensive corporate board experience, serving on the boards of a number of academic and professional organizations and public and private companies. A former Chairman of the American Board of Internal Medicine, he has served on the faculty and in professorial positions at the University of California, the University of Michigan, the University of Texas, and the Albert Einstein College of Medicine. He has authored or coauthored 130 peer-reviewed research papers and five textbooks. He is also Treasurer for the Board of Directors for Physicians for Human Rights. David earned his medical degree from the State University of NY at Buffalo and completed his pulmonary and critical care postgraduate training at the University of California at San Diego. He joined the Company in 2013 as a member of the Board of Directors.

David is an avid fly-fisherman and mixologist. He is a husband, father, and grandfather. Top

A cofounder of Origin, Howard Nelson has more than 25 years of management experience in the pharmaceutical, healthcare, and software industries. He began his career in Allied Signal/Honeywell but moved to pharmaceuticals, holding managerial business and commercial development roles at Pfizer and Bristol-Myers Squibb (BMS). He was responsible for concluding licensing deals for numerous products, notably Glucophage® (metformin), Avapro® (irbesartan), and Plavix® (clopidogrel).

He has held executive positions with a number of development-stage companies in medical products, biotechnology, and software. Howard serves on the Board of Trustees of the New Jersey Sharing Network as vice chairman. He received an MBA from Tulane University and an AB in Economics from Princeton University.

Howard works closely with Origin’s joint venture partner, Wheatsheaf Investments, to implement selected animal health and food security programs. He also develops corporate strategic plans across the agribusiness and human health divisions.

Originally from New Orleans, Howard is a former All-American swimmer and an avid golfer. He is currently an adjunct college professor lecturing on micro- and macroeconomics. Howard lives with his wife, horse, goat, and cats on their farm. Top

Johnny Fernandes is a finance executive with extensive international experience encompassing Europe, Asia, and the Americas. He has held senior management positions in Paris and New York at global beauty leader Coty, most recently serving as Senior Vice President of Corporate Working Capital and previously as Vice President of Finance for the Coty Beauty Division. Prior to joining Coty, Johnny worked in London at the insurer Domestic & General Group and food company H.J. Heinz. He has a BSc in biochemistry from St. Andrews University, Scotland and is a UK Chartered Accountant.

Johnny is married with two children and lives in Chatham, NJ. He enjoys playing golf and had spent a year trying (unsuccessfully) to make it his full-time occupation before Origin rescued him. Top

Vic has been involved in the healthcare industry for more than 50 years. He has been a board member of several biotechnology companies in the fields of oncology and Alzheimer’s research since he retired from Pfizer. During his 34-year career with Pfizer, Inc. he was involved in product development, marketing, and operational management. He was President of Pfizer's European operation for many years, residing in Brussels for nine of them. When returning to the US, he also headed Pfizer's worldwide Consumer Products Division and was a member of the Management Committee looking after Pfizer's operations globally. Vic is a graduate of Middlebury College and Columbia Business School. He and his wife, Elise, reside in Boca Raton, FL with other "outposts" in Colorado and Manhattan, NY. Top

Tony is currently a partner of Longbow Capital LLP and a Non-Executive Director of Polar Capital Global Healthcare Growth and Income Trust plc, Abzena plc, iPulse Limited and Domainex Limited, and has served on the boards of a number of quoted and emerging life science companies since 2006. Before this he held the position of Managing Director, Corporate Finance at J. P. Morgan Cazenove, with responsibility for healthcare and was involved in numerous IPOs, follow-on fund raisings, and mergers and acquisitions. Prior to this, Tony spent 20 over years in the City of London, becoming a partner of Cazenove & Co., the UK’s leading corporate broker. Tony has a BA and MSc in Biochemistry from the University of Oxford. He is a vocal supporter of England Rugby, a passion shared by his three children, and is a seasoned traveler, skier, scuba diver and consumer of fine red wine. Top

* Member of the Board of Directors